In recent years, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) therapy and Anti-PD1 therapy are widely used for advanced NSCLC (32–36). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.